$35M for Merrimack

A regulatory filing indicates that Cambridge, MA-based Merrimack Pharmaceuticals has raised $35 million of an $80 Series F financing round, according to PE Week Wire. No investors were named in the filing, but Merrimack’s $65 million Series E round, closed in April of 2006, included Jennison Associates, Modal Capital, Sorenson Development, WT Investment Advisors Fund, and funds advised by Noonday Asset Management, TPG-Axon Capital, and others.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy